← All trials
NCT01960075
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2015
- Primary completion
- Dec 1, 2019
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 795
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of VirginiaLead sponsor
- University of MichiganOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- Children's National Medical CenterOverall official - principal investigator
- University of VirginiaStudy chair
- University of MichiganCollaborator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of MinnesotaCollaborator
- Children's National Medical CenterCollaborator
- Medical University of South CarolinaCollaborator
- University of VirginiaReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.